Dr Reddy’s Laboratories (RDY) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Dr. Reddy’s Laboratories has launched Toripalimab in India, marking it as the first immuno-oncology drug approved for nasopharyngeal carcinoma (NPC) in the country. This launch positions India as the third nation globally to access this innovative treatment, following China and the U.S. Toripalimab has demonstrated a 48% reduction in disease progression risk when combined with standard chemotherapy, addressing a significant need for advanced NPC treatment.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
